KROS

Keros Therapeutics, Inc. (KROS) - 10-Q Summary for Period Ended September 30, 2025

Business Context and Reporting Period

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics targeting the TGF-β family of proteins. The reporting period covers the three and nine months ended September 30, 2025. The Company's lead product candidate, KER-065, is in development for neuromuscular diseases (specifically Duchenne muscular dystrophy), while its most advanced candidate, elritercept (KER-050), is being developed for myelodysplastic syndromes (MDS) and myelofibrosis. In December 2024, Keros entered into a global license agreement with Takeda Pharmaceuticals for elritercept (excluding China), which became effective in January 2025.

Key Financial Metrics

Liquidity: As of September 30, 2025, the Company held $693.5 million in cash and cash equivalents. Management believes this balance, less $375.0 million designated for return to stockholders, is sufficient to fund operations into the first half of 2028.

Material Changes vs. Prior Period

• Revenue Surge: Total revenue for the nine months ended September 30, 2025, increased to $243.7 million from $0.5 million in the prior year period. This was driven by a $200.0 million upfront payment and a $10.0 million development milestone from the Takeda license agreement, plus $38.1 million in transition service revenue.
• Profitability Shift: The Company reported a net income of $110.5 million for the nine months ended September 30, 2025, compared to a net loss of $141.3 million in the same period in 2024. The Q3 2025 net loss of $7.3 million contrasts with a Q3 2024 net loss of $53.0 million.
• Expense Reduction: Research and development expenses decreased by $16.3 million year-over-year for the nine-month period, primarily due to the transition of elritercept clinical activities to Takeda and the deprioritization of the cibotercept program.
• Restructuring: In May 2025, the Company implemented a restructuring plan reducing the workforce by approximately 45%, incurring one-time costs of approximately $3.1 million.

Guidance, Outlook, and Risks

• Clinical Outlook: Keros expects to initiate a Phase 2 clinical trial of KER-065 in Duchenne muscular dystrophy patients in the first quarter of 2026. The Phase 3 RENEW trial for elritercept in MDS patients has commenced, with the first patient dosed in July 2025.
• Capital Return Strategy: The Board has determined to return $375.0 million of excess capital to stockholders. This includes a $180.6 million share repurchase from ADAR1 Capital Management and Pontifax Venture Capital (completed October 2025) and an ongoing issuer tender offer for up to $194.4 million at $17.75 per share.
• Risks: Key risks include the uncertainty of clinical trial outcomes, reliance on third-party collaborators (Takeda and Hansoh) for elritercept commercialization, and the potential for the Takeda agreement to be terminated for convenience. The Company also faces risks related to the U.S. government shutdown and global geopolitical tensions impacting clinical operations.

Investor Verification Checklist

• Takeda Agreement Terms: Verify the specific termination rights and milestone payment schedules under the Takeda license agreement, particularly regarding the "for convenience" termination clause.
• Cash Runway Calculation: Confirm the $375 million capital return figure and its impact on the projected cash runway into 2028, ensuring it accounts for the ongoing tender offer.
• Restructuring Savings: Monitor the realization of the estimated $17 million in annualized cost savings from the 45% workforce reduction.
• KER-065 Timeline: Track the initiation of the Phase 2 trial for KER-065 in Q1 2026 as a critical near-term catalyst.
• Share Repurchase Impact: Assess the dilution or accretion effects of the completed and ongoing share repurchases on outstanding share count and per-share metrics.